LumiraDx files EUA request with FDA for SARS-CoV-2 & Flu A/B rapid test

Oct. 18, 2021

LumiraDx has submitted its SARS-CoV-2 & Flu A/B Test to the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA).

The microfluidic immunofluorescence assay can quickly verify infection for patients suspected of flu and/or COVID-19 to aid diagnosis and clinical decision making.

Run on the company’s point-of-care platform, the LumiraDx SARS-CoV-2 & Flu A/B Test is a rapid microfluidic immunofluorescence assay intended for the simultaneous detection of SARS-CoV-2, Influenza A, and Influenza B viral antigen direct from self or clinician collected nasal swab specimens from individuals suspected of viral infection consistent with COVID-19 by their healthcare provider within the first 12 days of the onset of symptoms.

The NIH Rapid Acceleration of Diagnostics initiative supported the development of the test, LumiraDX said.

Visit LumiraDX for more